n recent years, coronary stent implantation has become an established method for treating patients with coronary artery disease. However, in-stent restenosis attributable to intimal hyperplasia still occurs at a relatively high rate, not only with bare metal stents but also with drug eluting stents. 1,2 Conventional coronary angiography is still the domain of the assessment of 'in-stent' restenosis. However, angiography has limitations because of its invasiveness and high medical expense. Thus, a non-invasive alternative to assess the patency of the stented arterial segment would be highly desirable.
MSCT Scan Protocol
Coronary CT angiography was carried out using a 16-slice MSCT scanner (Sensation 16, Siemens, Forchheim, Germany) with a collimation of 16×0.75 mm and 0.42 s rotation time. The tube current was 250 mA at 120 kV. For contrast enhancement, 75 ml of contrast media (Iopamiron 370 mg/ml) were administered intravenously at rate of 3 ml/s, followed by a 30 ml saline chaser bolus administered using a power injector. Images were then acquired during an inspiratory breath hold. An electrocardiogram (ECG) was simultaneously recorded during the MSCT examination for retrospective gating of data. ECG-gated image reconstruction was carried out using a medium-sharp body convolution kernel (B30f) in the mid-to end-diastolic phase of the cardiac cycle using between 30% and 70% relative delay.
Quantitative Invasive Coronary Angiography
Conventional coronary angiograms were evaluated by an experienced observer without knowledge of the data gathered using MSCT. Quantitative coronary angiography (QCA) served as the gold standard for stenosis detection. Adequate stent patency on QCA was defined as in-stent or peri-stent stenosis reducing luminal diameter by less than 50%.
Data Analysis
To assess the patency of coronary stents, images produced by multiplanar reconstruction (MPR) and/or curved MPR were evaluated by 2 experienced observers (reader 1 and 2) unaware of the catheterization results. Initially, each stent was assigned an image score of 1 (poor image quality or uninterpretable), 2 (adequate image quality), or 3 (good image quality) based on the classification mentioned by Schuijf et al. 4 Stent images with a score of 2 or 3 were evaluated and included in our statistical analysis, but those with a score of 1 were not. Once an image score was assigned and stent patency evaluated, we analyzed factors determining the quality of the MPR images, including stent diameter, stent strut thickness and coronary calcification. To assess the effects of specific characteristics on image quality, stents were categorized by diameter (2.5 mm, 3.0 mm, 3.5 mm, or 4.0 mm) and as having either thick struts (≥0.005 inches; Trister stent, BX velocity stent, S670 stent) or thin struts (<0.005 inches; Penta stent, Duraflex stent).
Implanted stents were deemed adequately patent when the longitudinal MPR images revealed: (i) no disruption of coronary flow distal to the implanted stent; (ii) peri-stent stenosis was no more than 50%; and (iii) there was no contrast defect in the stent. Stents not meeting at least one of the 3 criteria were regarded as restenosis. In the case (image score 3) that had difficulty with evaluation of restenosis in the stent by longitudinal MPR re-construction, cross-sectional MPR images of the target stents were also examined. In cross-section analysis, we calculated the area stenosis ([vessel area: inner margin of stent artifact] -[contrast enhanced area]/vessel area ×100). More than 50% area stenosis was also regarded as restenosis. Inter-observer agreement in the interpretation of the stent restenosis was high ( =0.77) among 35 stented segnents, and higher ( = 0.86) among 21 stents ≥3.5 mm in diameter (Cohen statistics).
Furthermore, to quantitatively evaluate the luminal patency in the coronary stent, the CT attenuation values of the minimum luminal site within the stent lumen (stent site) and the normal luminal site outside the stent (reference site) were measured with a region-of-interest (ROI) technique in the cross-sections of target vessels. The ROI of the stent site was placed by using the free-hand trace in stent lumen without inclusion of the stent struts and the ROI of the reference site was placed in the center of normal luminal site (the size of all ROI with 12 pixels , Fig 1) . The relative value of the stent site was expressed as the equation (stent site attenuation values/reference site attenuation value). Then CT attenuation measurements were compared between restenotic stent lumens and non-restenotic stent lumens.
Statistical Analysis
Data are presented as means ± standard deviation and were compared by analysis of variance followed by Fisher's protected least significance difference test. Average image scores were then calculated for each category. Sensitivity, specificity, positive and negative predictive value for detection of stent patency (also determined by QCA) were determined for each stent. Multivariate logistic regression analysis was performed to determine independent factors determining the quality of images of stent lumens. Values of p<0.05 were considered significant. 
Results

Clinical Characteristics of the Study Group
The clinical characteristics of the patients and the coronary stents used are summarized in Table 1 . The average interval between MSCT and conventional angiography was 39.0±21.8 days. At the time of MSCT, the mean heart rate was 54±6 beats/min (range: 40 to 71 beats/min). The mean scan duration was 19±2 s (range: 14 to 25 s). MSCT was performed 6.2±4.0 months (range: 3 to 24 months) after stent implantation in 28 patients (38 stents) and 8.3±3.2 months (range: 5 to 11 months) after target vessel revascularization for in-stent restenosis in 4 patients (4 stents). MSCT was performed successfully in all subjects. Sixteen stents were implanted in the left anterior descending coronary artery, 9 in the left circumflex coronary artery and 17 in the right coronary artery. The diameters of the implanted stents ranged from 2.5 to 4.0 mm: 5 stents were 2.5 mm in diameter; 5 stents were 3.0 mm; 16 stents were 3.5 mm; and 9 stents were 4.0 mm. Five different types of stent had been used: 28 Multilink Penta (Guidant), 4 Multilink Trister (Guidant), 3 Bx-Velocity (Cordis), 3 S670 (Medtronic) and 4 Duraflex (Goodman).
Visibility of Coronary Stent Lumens
Based on the image quality, 7 stents (17%) were assigned an image score of 1, 2 (5%) an image score of 2, and 33 (78%) an image score of 3. Fig 2 shows representative cases for each image score. We next assessed the factors that could potentially affect image quality. Examination of the relationship between stent diameter and the quality of the stent images showed that as stent diameter declined, there was a significant decline in image quality (Figs 3,4 ; Table 2 ). Similarly, calcification at the stent site significantly (p<0.01) diminished the quality of luminal images of implanted stents (Table 2 ). Coronary artery calcification at the stent site was detected in 12 stents. The average image score was 2.4±1.0 for stents with calcification and 2.7±0.7 for stents without calcification. However, strut thickness had no significant effect on image quality (Fig 5, Table 2 ).
Evaluation of Stent Patency
Before evaluating the luminal patency of implanted coronary stents during the chronic phase, 7 stents receiving an image score of 1 were disallowed because of poor image quality. The causes of poor quality were small diameter (2.5 mm) in 4 cases, severe calcification around the stent in 2 cases, and a motion artifact in 1 case. Among the 35 stents receiving an image score of 2 or 3, 27 were deemed to be adequately patent based on MSCT examination; the other 8 were diagnosed as having an in-stent or peri-stent restenotic lesion (Fig 6) . In the QCA study, by contrast, 6 of the 35 stents were diagnosed as having in-stent or peristent restenosis. One in-stent restenotic lesion was underestimated using MSCT, despite adequate image quality, and restenosis was overestimated in 3 stents using MSCT and were counted as false-positives (2 of those stents had calcifications). Among the 35 stents receiving an image score 2 or 3, the sensitivity of MSCT for evaluating stent patency during the chronic phase was 83% (reader 1) and 100% (reader 2), specificity was 90% (reader 1) and 93% (reader 2), positive predictive value was 63% (reader 1) and 75% (reader 2), and negative predictive value was 96% (reader 1) and 100% (reader 2).
We also separately assessed the diagnostic accuracy of MSCT in patients with larger stents (≥3.5 mm) because all stents ≥3.5 mm in diameter showed good image quality (score 3), and because the in-stent lumen of some smaller stents (≤3.0 mm) tended to be obscured by stent-related artifacts or coronary calcification. Among 21 stents ≥3.5 mm in diameter, the sensitivity was 100% (reader 1) and 100% (reader 2), specificity was 89% (reader 1) and 94% (reader 2), positive predictive value was 60% (reader 1) and 75% (reader 2), and negative predictive value was 100% (reader 1) and 100% (reader 2) ( Table 3) .
CT Attenuation Values of In-Stent Lumen
With conventional coronary angiography, 6 stents were diagnosed as restenosis and 29 stents as non-restenosis. The mean attenuation value of stent site measured on the restenotic stents (227.5±70.3) was significantly lower than that on the non-restenotic stents (409.9±84.1; p<0.01). Similarly, the mean relative value on the restenotic stents (0.68±0.23) was significantly lower than that on the nonrestenotic stents (1.24±0.19; p<0.01). In particular, all 5 patients whose relative value was less than 0.9 were shown to have in-stent restenosis. These results indicate that larger amount of contrast agent was filled in non-restenotic stents compared to restenotic stents (Table 4) .
Discussion
Over the past 15 years, coronary artery stenting has become an established medical treatment for patients with ischemic heart disease, and its use continues to increase rapidly, as the incidence of long-term restenosis is significantly lower with stenting than with ordinary balloon angioplasty. 5 Nonetheless, the in-stent restenosis rate is still high (20-30%) for bare metal stents, 5, 6 which usually necessitates follow-up examination using coronary angiography. Although conventional coronary angiography is still considered as the "Holy Grail" for the diagnosis of coronary artery disease, 7 recent development in diagnostic modalities such as magnetic resonance angiography (MRA), electron beam CT (EBCT), and MSCT has allowed non-invasive visualization of the coronary artery. MRA might be the most promising method because it does not require radiation or contrast media, but its spatial resolution is still limited. 8 Moreover, visualization of coronary artery stents is not possible by MRA. 3 EBCT also has limitations in spatial resolution and it is not suitable for the assessment of stent patency. 9 With the development of MSCT, however, it has become possible to visualize the precise anatomy of the moving heart. [10] [11] [12] Moreover, the recently introduced 16-slice MSCT system, which allows simultaneous acquisition of 16 submillimeter slices, enables more detailed imaging, not only of stenosed coronary arteries but also of stents implanted within coronary arteries. 13 Our aim, therefore, was to evaluate the usefulness of 16-slice MSCT for clinical evaluation of the patency of metallic stents within coronary arteries. Our findings using 16-slice MSCT indicate that comparatively small stent diameters (≤3.0 mm) and coronary calcification, but not stent strut thickness, significantly impair imaging of the stent lumen using 16-slice MSCT. It has been previously reported that in unmoving organs, such as brain or liver, arteries with diameters as small as 1.0 mm can be imaged using 16-slice MSCT. 14 In the case of coronary arteries within a moving heart, there is sufficient temporal and spatial resolution to image coronary stents with diameters ≥3.5 mm. It was previously reported that with 4-slice MSCT even minor calcification can significantly impair the quality of coronary artery images. 10, 15, 16 By contrast, more reports have shown that the quality of coronary artery images is not significantly impaired by minor calcification when using 16-slice MSCT. 17 In our study population, multiple regression analysis revealed that coronary arterial calcification at the stent site significantly reduced the quality of luminal images; however, images of only 1 of 12 stents with calcification was determined to be uninterpretable as a result of the severity of the calcification. However, when a stent is implanted within a coronary segment with calcification, especially with heavy calcification, it is likely that 16-slice MSCT will not be sufficient to obtain interpretable images of the stent lumen.
The results of our multivariate logistic regression analysis indicate that stent strut thickness does not affect image quality. By contrast, Schuijf et al suggested that thicker struts tended to make images uninterpretable because stents with thicker struts were more affected by partial volume effect because of high-density texture. 4 The reason for the discrepancy between our findings and those of Schuijf et al is not clear, although several factors related to the scanning conditions could influence the severity of the artifact from metallic stents. It is noteworthy, for instance, that heart rate at the time of CT examination was substantially lower in our study population than in theirs (54±6 vs 65±11 beats/min).
In stents with good image quality, we found that the sensitivity and specificity of 16-slice MSCT were sufficient to assess coronary artery stent patency. In particular, the presence of contrast enhancement of the vessel distal to the stent was a potent sign of patency; conversely, the near absence of distal run-off almost certainly indicated severe stenosis or total stent occlusion. The results of Cohen's statistics shows that the interpretation of MSCT images for evaluating coronary stent patency has good inter-observer agreement.
We also showed that the intra-luminal CT attenuation value of restenotic stents was lower than that of non-restenotic stents. Furthermore, all the stents with relative value ([stent site]/[reference site]) less than 0.9 was revealed to have in-stent restenosis. Supporting our observation, Suzuki et al suggested an in vitro study that significant in-stent restenosis was indicated by lower luminal attenuation inside the stents than that in the unstented portion. 18 Although it is impossible to precisely distinguish thrombus and intimal hyperplasia within the stent lumen in the present MSCT technology, we hope that as much as spatial and temporal resolution improves, it will become possible to quantitatively diagnose in-stent restenosis by using CT attenuation value.
Recently, drug-eluting stents (DES) were reported to be associated with a lower rate (3-5%) of restenosis. 19 In that regard, the very high specificity and negative predictive value for the detection of significant in-stent restenosis we obtained suggests that 16-slice MSCT could be highly useful for evaluating DES luminal patency. However, in routine clinical settings, many patients are treated with relatively small stents having diameters of 2.5 mm or 3.0 mm. Further improvement in spatial resolution and temporal resolution will be necessary for MSCT to become a routine diagnostic procedure for the evaluation of stent patency (16-slice MSCT already has submillimeter spatial resolution, and the temporal resolution mainly depends on the gantry rotation time rather than on the algorithm used).
Limitations of MSCT for the assessment of stent patency include high heart rates, arrhythmias and disability to perform breath holding. Currently available 64-slice MSCT might overcome these technical limitations by improving temporal resolution as short as 160 ms and total scan time less than 5 s.
Conclusions
The 16-slice MSCT can provide useful and valuable clinical information when evaluating stent patency during the chronic phase after implantation, especially in patients treated with a relatively large diameter coronary stent (≥3.5 mm). Further improvements in image quality will be necessary before MSCT is routinely used for follow up after coronary arterial stent implantation.
